Timothy R. Holzer, Ph.D.
Affiliations: | 2005 | Purdue University, West Lafayette, IN, United States |
Area:
Biochemistry, Molecular BiologyGoogle:
"Timothy Holzer"Mean distance: (not calculated yet) | S | N | B | C | P |
Parents
Sign in to add mentor| James D. Forney | grad student | 2005 | Purdue | |
| (Molecular and genomic analysis of mRNA stability in Leishmania mexicana.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Nasir A, Falcon BL, Wang D, et al. (2018) Vascular and tumor cell expression of VEGFR2 and molecular subtyping: An innovative biomarker approach in bladder cancer. Journal of Clinical Oncology. 36: 497-497 |
| LeBlanc AK, Oakley GJ, Lowery CD, et al. (2018) Abstract LB-B01: The anti-platelet-derived growth factor receptor α antibody olaratumab (Lartruvo) increases overall survival in metastatic mouse models of human osteosarcoma Molecular Cancer Therapeutics. 17 |
| Holzer TR, O'Neill Reising L, Credille KM, et al. (2016) Variability in Platelet-Derived Growth Factor Receptor Alpha Antibody Specificity May Impact Clinical Utility of Immunohistochemistry Assays. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society |
| Holzer TR, Nedderman DM, Nasir A. (2015) Abstract 4175: Robust immunohistochemical assay to characterize human cancer tissues for prevalence of vascular endothelial growth factor receptor 3 (VEGFR3) Cancer Research. 75: 4175-4175 |
| Nasir A, Holzer TR, Man M, et al. (2015) Abstract 4161: Differential expression of VEGFR2 Protein in HER2 positive primary human breast cancer: Potential relevance to newer anti-angiogenic therapies Cancer Research. 75: 4161-4161 |
| Holzer TR, Fulford AD, Reising LO, et al. (2015) Abstract 4157: Heterogeneity of vascular endothelial growth factor receptors 1, 2, and 3 in human non-small cell lung carcinomas Cancer Research. 75: 4157-4157 |
| Yan SB, Um SL, Peek VL, et al. (2014) Abstract 4403: Preclinical evaluation of LY2801653, an orally bioavailable small molecule oncokinase inhibitor, in cholangiocarcinoma models Cancer Research. 74: 4403-4403 |
| Holzer TR, O'Neill LA, Nedderman DM, et al. (2014) Abstract 3007: Heterogeneity of vascular endothelial growth factor receptors 1, 2, and 3 in primary human colorectal adenocarcinoma Cancer Research. 74: 3007-3007 |
| Holzer TR, Falcon BL, Fulford AD, et al. (2014) Abstract 3004: VEGFR2 expression and vascular phenotyping demonstrate different patterns of tumor angiogenesis in human gastric and breast cancers Cancer Research. 74: 3004-3004 |
| Holzer TR, Fulford AD, Nedderman DM, et al. (2013) Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lung. Plos One. 8: e80292 |